<?xml version="1.0" encoding="UTF-8"?>
<p id="p0025">Recent studies have shown that diabetes mellitus (DM) is one of the most common comorbidities of COVID-19, with a prevalence ranging from 5.3% to 58.0% 
 <xref rid="b0020" ref-type="bibr">[4]</xref>, 
 <xref rid="b0025" ref-type="bibr">[5]</xref>, 
 <xref rid="b0030" ref-type="bibr">[6]</xref>. Diabetes has been associated with an increased mortality in previous viral epidemics, such as the outbreak of SARS-CoV-1 and Middle East respiratory syndrome coronavirus 
 <xref rid="b0035" ref-type="bibr">[7]</xref>, 
 <xref rid="b0040" ref-type="bibr">[8]</xref>. Similar conclusions were reported in the pandemic of SARS-CoV-2. Some studies have suggested that diabetes is a risk factor for the poor prognosis of COVID-19 
 <xref rid="b0020" ref-type="bibr">[4]</xref>, 
 <xref rid="b0045" ref-type="bibr">[9]</xref>, 
 <xref rid="b0050" ref-type="bibr">[10]</xref>, while some studies reported that patients with diabetes seemed not to have a higher mortality risk 
 <xref rid="b0055" ref-type="bibr">[11]</xref>, 
 <xref rid="b0060" ref-type="bibr">[12]</xref>. Data regarding the impact of diabetes on the prognosis of COVID-19 patients are scant and controversial.
</p>
